Mitochondria are multifunctional organelles with diverse roles including energy production and distribution, apoptosis, eliciting host immune response, and causing diseases and aging. Mitochondria-mediated immune responses might be an evolutionary adaptation by which mitochondria might have prevented the entry of invading microorganisms thus establishing them as an integral part of the cell. This makes them a target for all the invading pathogens including viruses. Viruses either induce or inhibit various mitochondrial processes in a highly specific manner so that they can replicate and produce progeny. Some viruses encode the Bcl2 homologues to counter the proapoptotic functions of the cellular and mitochondrial proteins. Others modulate the permeability transition pore and either prevent or induce the release of the apoptotic proteins from the mitochondria. Viruses like Herpes simplex virus 1 deplete the host mitochondrial DNA and some, like human immunodeficiency virus, hijack the host mitochondrial proteins to function fully inside the host cell. All these processes involve the participation of cellular proteins, mitochondrial proteins, and virus specific proteins. This review will summarize the strategies employed by viruses to utilize cellular mitochondria for successful multiplication and production of progeny virus. 1. Introduction 1.1. Mitochondria Mitochondria are cellular organelles found in the cytoplasm of almost all eukaryotic cells. One of their important functions is to produce and provide energy to the cell in the form of ATP, which help in proper maintenance of the cellular processes, thus making them indispensable for the cell. Besides acting as a powerhouse for the cell, they act as a common platform for the execution of a variety of cellular functions in normal or microorganism infected cells. Mitochondria have been implicated in aging [1, 2], apoptosis [3–7], the regulation of cell metabolism [4, 8], cell-cycle control [9–11], development of the cell [12–14], antiviral responses [15], signal transduction [16], and diseases [17–20]. Although all mitochondria have the same architecture, they vary greatly in shape and size. The mitochondria are composed of outer mitochondrial membrane, inner mitochondrial membrane, intermembrane space (space between outer and inner membrane), and matrix (space within inner mitochondrial membrane). The outer membrane is a smooth phospholipid bilayer, with different types of proteins imbedded in it [21]. The most important of them are the porins, which freely allow the transport (export and import) of
References
[1]
D. C. Wallace, “A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine,” Annual Review of Genetics, vol. 39, pp. 359–407, 2005.
[2]
D. C. Chan, “Mitochondria: dynamic organelles in disease, aging, and development,” Cell, vol. 125, no. 7, pp. 1241–1252, 2006.
[3]
A. Antignani and R. J. Youle, “How do Bax and Bak lead to permeabilization of the outer mitochondrial membrane?” Current Opinion in Cell Biology, vol. 18, no. 6, pp. 685–689, 2006.
[4]
H. Chen and D. C. Chan, “Emerging functions of mammalian mitochondrial fusion and fission,” Human Molecular Genetics, vol. 14, no. 2, pp. R283–R289, 2005.
[5]
I. Gradzka, “Mechanisms and regulation of the programmed cell death,” Postepy Biochemii, vol. 52, no. 2, pp. 157–165, 2006.
[6]
H. M. McBride, M. Neuspiel, and S. Wasiak, “Mitochondria: more than just a powerhouse,” Current Biology, vol. 16, no. 14, pp. R551–R560, 2006.
[7]
G. Kroemer, L. Galluzzi, and C. Brenner, “Mitochondrial membrane permeabilization in cell death,” Physiological Reviews, vol. 87, no. 1, pp. 99–163, 2007.
[8]
C. A. Mannella, “Structure and dynamics of the mitochondrial inner membrane cristae,” Biochimica et Biophysica Acta, vol. 1763, no. 5-6, pp. 542–548, 2006.
[9]
D. G. Hardie, J. W. Scott, D. A. Pan, and E. R. Hudson, “Management of cellular energy by the AMP-activated protein kinase system,” The FEBS Letters, vol. 546, no. 1, pp. 113–120, 2003.
[10]
R. G. Jones, D. R. Plas, S. Kubek et al., “AMP-activated protein kinase induces a p53-dependent metabolic checkpoint,” Molecular Cell, vol. 18, no. 3, pp. 283–293, 2005.
[11]
S. Mandal, P. Guptan, E. Owusu-Ansah, and U. Banerjee, “Mitochondrial regulation of cell cycle progression during development as revealed by the tenured mutation in Drosophila,” Developmental Cell, vol. 9, no. 6, pp. 843–854, 2005.
[12]
L. E. Bakeeva, Y. S. Chentsov, and V. P. Skulachev, “Mitochondrial framework (reticulum mitochondriale) in rat diaphragm muscle,” Biochimica et Biophysica Acta, vol. 501, no. 3, pp. 349–369, 1978.
[13]
L. E. Bakeeva, Y. S. Chentsov, and V. P. Shulachev, “Intermitochondrial contacts in myocardiocytes,” Journal of Molecular and Cellular Cardiology, vol. 15, no. 7, pp. 413–420, 1983.
[14]
S. Honda and S. Hirose, “Stage-specific enhanced expression of mitochondrial fusion and fission factors during spermatogenesis in rat testis,” Biochemical and Biophysical Research Communications, vol. 311, no. 2, pp. 424–432, 2003.
[15]
R. B. Seth, L. Sun, C. K. Ea, and Z. J. Chen, “Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-κB and IRF3,” Cell, vol. 122, no. 5, pp. 669–682, 2005.
[16]
E. Bossy-Wetzel, M. J. Barsoum, A. Godzik, R. Schwarzenbacher, and S. A. Lipton, “Mitochondrial fission in apoptosis, neurodegeneration and aging,” Current Opinion in Cell Biology, vol. 15, no. 6, pp. 706–716, 2003.
[17]
C. W. Olanow and W. G. Tatton, “Etiology and pathogenesis of Parkinson's disease,” Annual Review of Neuroscience, vol. 22, pp. 123–144, 1999.
[18]
S. K. van den Eeden, C. M. Tanner, A. L. Bernstein et al., “Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity,” The American Journal of Epidemiology, vol. 157, no. 11, pp. 1015–1022, 2003.
[19]
L. J. Martin, “Mitochondriopathy in Parkinson disease and amyotrophic lateral sclerosis,” Journal of Neuropathology and Experimental Neurology, vol. 65, no. 12, pp. 1103–1110, 2006.
[20]
R. McFarland, R. W. Taylor, and D. M. Turnbull, “Mitochondrial disease—its impact, etiology, and pathology,” in Current Topics in Developmental Biology, J. C. St John, Ed., pp. 113–155, Academic Press, New York, NY, USA, 2007.
[21]
D. Rapaport, “Finding the right organelle. Targeting signals in mitochondrial outer-membrane proteins,” EMBO Reports, vol. 4, no. 10, pp. 948–952, 2003.
[22]
M. Amiry-Moghaddam, H. Lindland, S. Zelenin et al., “Brain mitochondria contain aquaporin water channels: evidence for the expression of a short AQP9 isoform in the inner mitochondrial membrane,” FASEB Journal, vol. 19, no. 11, pp. 1459–1467, 2005.
[23]
G. Calamita, D. Ferri, P. Gena et al., “The inner mitochondrial membrane has aquaporin-8 water channels and is highly permeable to water,” The Journal of Biological Chemistry, vol. 280, no. 17, pp. 17149–17153, 2005.
[24]
B. Yang, D. Zhao, and A. S. Verkman, “Evidence against functionally significant aquaporin expression in mitochondria,” The Journal of Biological Chemistry, vol. 281, no. 24, pp. 16202–16206, 2006.
[25]
G. S. Shadel and D. A. Clayton, “Mitochondrial DNA maintenance in vertebrates,” Annual Review of Biochemistry, vol. 66, pp. 409–435, 1997.
[26]
E. A. Shoubridge, “The ABcs of mitochondrial transcription,” Nature Genetics, vol. 31, no. 3, pp. 227–228, 2002.
[27]
G. Burger, M. W. Gray, and B. F. Lang, “Mitochondrial genomes: anything goes,” Trends in Genetics, vol. 19, no. 12, pp. 709–716, 2003.
[28]
W. Neupert and J. M. Herrmann, “Translocation of proteins into mitochondria,” Annual Review of Biochemistry, vol. 76, pp. 723–749, 2007.
[29]
A. Chacinska, C. M. Koehler, D. Milenkovic, T. Lithgow, and N. Pfanner, “Importing mitochondrial proteins: machineries and mechanisms,” Cell, vol. 138, no. 4, pp. 628–644, 2009.
[30]
O. Schmidt, N. Pfanner, and C. Meisinger, “Mitochondrial protein import: from proteomics to functional mechanisms,” Nature Reviews Molecular Cell Biology, vol. 11, no. 9, pp. 655–667, 2010.
[31]
M. van der Laan, D. P. Hutu, and P. Rehling, “On the mechanism of preprotein import by the mitochondrial presequence translocase,” Biochimica et Biophysica Acta, vol. 1803, no. 6, pp. 732–739, 2010.
[32]
S. J. Habib, T. Waizenegger, M. Lech, W. Neupert, and D. Rapaport, “Assembly of the TOB complex of mitochondria,” The Journal of Biological Chemistry, vol. 280, no. 8, pp. 6434–6440, 2005.
[33]
T. Schwann, “Microscopical researches into the accordance in the structure and growth of animals and plants,” in Contributions to Phytogenesis, M. J. Schleiden, Ed., Sydenham Society, London, UK, 1847.
[34]
M. J. Berridge, M. D. Bootman, and P. Lipp, “Calcium—a life and death signal,” Nature, vol. 395, no. 6703, pp. 645–648, 1998.
[35]
D. R. Green and J. C. Reed, “Mitochondria and apoptosis,” Science, vol. 281, no. 5381, pp. 1309–1312, 1998.
[36]
S. V. Chorna, V. I. Dosenko, N. A. Strutyns'ka, H. L. Vavilova, and V. F. Sahach, “Increased expression of voltage-dependent anion channel and adenine nucleotide translocase and the sensitivity of calcium-induced mitochondrial permeability transition opening pore in the old rat heart,” Fiziolohichnyǐ Zhurnal, vol. 56, no. 4, pp. 19–25, 2010.
[37]
Y. Liu, L. Gao, Q. Xue et al., “Voltage-dependent anion channel involved in the mitochondrial calcium cycle of cell lines carrying the mitochondrial DNA A4263G mutation,” Biochemical and Biophysical Research Communications, vol. 404, no. 1, pp. 364–369, 2011.
[38]
Y. Kirichok, G. Krapivinsky, and D. E. Clapham, “The mitochondrial calcium uniporter is a highly selective ion channel,” Nature, vol. 427, no. 6972, pp. 360–364, 2004.
[39]
T. E. Gunter and K. K. Gunter, “Uptake of calcium by mitochondria: transport and possible function,” IUBMB Life, vol. 52, no. 3–5, pp. 197–204, 2002.
[40]
G. Szabadkai, K. Bianchi, P. Várnai et al., “Chaperone-mediated coupling of endoplasmic reticulum and mitochondrial Ca2+ channels,” Journal of Cell Biology, vol. 175, no. 6, pp. 901–911, 2006.
[41]
A. P. Halestrap, “What is the mitochondrial permeability transition pore?” Journal of Molecular and Cellular Cardiology, vol. 46, no. 6, pp. 821–831, 2009.
[42]
A. P. Halestrap, “A pore way to die: the role of mitochondria in reperfusion injury and cardioprotection,” Biochemical Society Transactions, vol. 38, no. 4, pp. 841–860, 2010.
[43]
M. Hüttemann, I. Lee, A. Pecinova, P. Pecina, K. Przyklenk, and J. W. Doan, “Regulation of oxidative phosphorylation, the mitochondrial membrane potential, and their role in human disease,” Journal of Bioenergetics and Biomembranes, vol. 40, no. 5, pp. 445–456, 2008.
[44]
V. Petronilli, B. Persson, M. Zoratti, J. Rydstrom, and G. F. Azzone, “Flow-force relationships during energy transfer between mitochondrial proton pumps,” Biochimica et Biophysica Acta, vol. 1058, no. 2, pp. 297–303, 1991.
[45]
W. Xia, Y. Shen, H. Xie, and S. Zheng, “Involvement of endoplasmic reticulum in hepatitis B virus replication,” Virus Research, vol. 121, no. 2, pp. 116–121, 2006.
[46]
W. J. H. Koopman, L. G. J. Nijtmans, C. E. J. Dieteren et al., “Mammalian mitochondrial complex I: biogenesis, regulation, and reactive oxygen species generation,” Antioxidants and Redox Signaling, vol. 12, no. 12, pp. 1431–1470, 2010.
[47]
S. A. Susin, H. K. Lorenzo, N. Zamzami et al., “Molecular characterization of mitochodrial apoptosis-inducing factor,” Nature, vol. 397, no. 6718, pp. 441–446, 1999.
[48]
R. S. Balaban, “The role of Ca2+ signaling in the coordination of mitochondrial ATP production with cardiac work,” Biochimica et Biophysica Acta, vol. 1787, no. 11, pp. 1334–1341, 2009.
[49]
M. E. Wernette, R. S. Ochs, and H. A. Lardy, “Ca2+ stimulation of rat liver mitochondrial glycerophosphate dehydrogenase,” The Journal of Biological Chemistry, vol. 256, no. 24, pp. 12767–12771, 1981.
[50]
J. G. McCormack and R. M. Denton, “Mitochondrial Ca2+ transport and the role of intramitochondrial Ca2+ in the regulation of energy metabolism,” Developmental Neuroscience, vol. 15, no. 3–5, pp. 165–173, 1993.
[51]
V. Mildaziene, R. Baniene, Z. Nauciene et al., “Calcium indirectly increases the control exerted by the adenine nucleotide translocator over 2-oxoglutarate oxidation in rat heart mitochondria,” Archives of Biochemistry and Biophysics, vol. 324, no. 1, pp. 130–134, 1995.
[52]
R. A. Haworth, D. R. Hunter, and H. A. Berkoff, “Contracture in isolated adult rat heart cells. Role of Ca2+, ATP, and compartmentation,” Circulation Research, vol. 49, no. 5, pp. 1119–1128, 1981.
[53]
J. A. Copello, S. Barg, A. Sonnleitner et al., “Differential activation by Ca2+, ATP and caffeine of cardiac and skeletal muscle ryanodine receptors after block by Mg2+,” Journal of Membrane Biology, vol. 187, no. 1, pp. 51–64, 2002.
[54]
P. Nasr, H. I. Gursahani, Z. Pang et al., “Influence of cytosolic and mitochondrial Ca2+, ATP, mitochondrial membrane potential, and calpain activity on the mechanism of neuron death induced by 3-nitropropionic acid,” Neurochemistry International, vol. 43, no. 2, pp. 89–99, 2003.
[55]
J. D. Johnston and M. D. Brand, “The mechanism of Ca2+ stimulation of citrulline and N-acetylglutamate synthesis by mitochondria,” Biochimica et Biophysica Acta, vol. 1033, no. 1, pp. 85–90, 1990.
[56]
J. D. McGivan, N. M. Bradford, and J. Mendes-Mour？o, “The regulation of carbamoyl phosphate synthase activity in rat liver mitochondria,” Biochemical Journal, vol. 154, no. 2, pp. 415–421, 1976.
[57]
T. I. Peng and M. J. Jou, “Oxidative stress caused by mitochondrial calcium overload,” Annals of the New York Academy of Sciences, vol. 1201, pp. 183–188, 2010.
[58]
K. Lund and B. Ziola, “Cell sonicates used in the analysis of how measles and herpes simplex type 1 virus infections influence Vero cell mitochondrial calcium uptake,” Canadian Journal of Biochemistry and Cell Biology, vol. 63, no. 11, pp. 1194–1197, 1985.
[59]
Y. Li, D. F. Boehning, T. Qian, V. L. Popov, and S. A. Weinman, “Hepatitis C virus core protein increases mitochondrial ROS production by stimulation of Ca2+ uniporter activity,” FASEB Journal, vol. 21, no. 10, pp. 2474–2485, 2007.
[60]
R. V. Campbell, Y. Yang, T. Wang et al., “Effects of hepatitis C core protein on mitochondrial electron transport and production of reactive oxygen species,” Methods in Enzymology, vol. 456, pp. 363–380, 2009.
[61]
G. Gong, G. Waris, R. Tanveer, and A. Siddiqui, “Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-κB,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 17, pp. 9599–9604, 2001.
[62]
M. Kalamvoki and P. Mavromara, “Calcium-dependent calpain proteases are implicated in processing of the hepatitis C virus NS5A protein,” Journal of Virology, vol. 78, no. 21, pp. 11865–11878, 2004.
[63]
N. Dionisio, M. V. Garcia-Mediavilla, S. Sanchez-Campos et al., “Hepatitis C virus NS5A and core proteins induce oxidative stress-mediated calcium signalling alterations in hepatocytes,” Journal of Hepatology, vol. 50, no. 5, pp. 872–882, 2009.
[64]
M. K. Baum, S. Sales, D. T. Jayaweera et al., “Coinfection with hepatitis C virus, oxidative stress and antioxidant status in HIV-positive drug users in Miami,” HIV Medicine, vol. 12, no. 2, pp. 78–86, 2011.
[65]
G. A. Cook and S. J. Opella, “NMR studies of p7 protein from hepatitis C virus,” European Biophysics Journal, vol. 39, no. 7, pp. 1097–1104, 2010.
[66]
S. D. C. Griffin, R. Harvey, D. S. Clarke, W. S. Barclay, M. Harris, and D. J. Rowlands, “A conserved basic loop in hepatitis C virus p7 protein is required for amantadine-sensitive ion channel activity in mammalian cells but is dispensable for localization to mitochondria,” Journal of General Virology, vol. 85, no. 2, pp. 451–461, 2004.
[67]
M. J. Bouchard, L. H. Wang, and R. J. Schneider, “Calcium signaling by HBx protein in hepatitis B virus DNA replication,” Science, vol. 294, no. 5550, pp. 2376–2378, 2001.
[68]
Y. Choi, S. G. Park, J. H. Yoo, and G. Jung, “Calcium ions affect the hepatitis B virus core assembly,” Virology, vol. 332, no. 1, pp. 454–463, 2005.
[69]
M. Foti, L. Cartier, V. Piguet et al., “The HIV Nef protein alters Ca2+ signaling in myelomonocytic cells through SH3-mediated protein-protein interactions,” The Journal of Biological Chemistry, vol. 274, no. 49, pp. 34765–34772, 1999.
[70]
A. Manninen and K. Saksela, “HIV-1 Nef interacts with inositol trisphosphate receptor to activate calcium signaling in T cells,” Journal of Experimental Medicine, vol. 195, no. 8, pp. 1023–1032, 2002.
[71]
S. Kinoshita, L. Su, M. Amano, L. A. Timmerman, H. Kaneshima, and G. P. Nolan, “The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells,” Immunity, vol. 6, no. 3, pp. 235–244, 1997.
[72]
M. C. Ruiz, J. Cohen, and F. Michelangeli, “Role of Ca2+ in the replication and pathogenesis of rotavirus and other viral infections,” Cell Calcium, vol. 28, no. 3, pp. 137–149, 2000.
[73]
P. Tian, M. K. Estes, Y. Hu, J. M. Ball, C. Q. Zeng, and W. P. Schilling, “The rotavirus nonstructural glycoprotein NSP4 mobilizes Ca2+ from the endoplasmic reticulum,” Journal of Virology, vol. 69, no. 9, pp. 5763–5772, 1995.
[74]
Y. Díaz, M. E. Chemello, F. Pe？a et al., “Expression of nonstructural rotavirus protein NSP4 mimics Ca2+ homeostasis changes induced by rotavirus infection in cultured cells,” Journal of Virology, vol. 82, no. 22, pp. 11331–11343, 2008.
[75]
J. L. Zambrano, Y. Díaz, F. Pe？a et al., “Silencing of rotavirus NSP4 or VP7 expression reduces alterations in Ca2+ homeostasis induced by infection of cultured cells,” Journal of Virology, vol. 82, no. 12, pp. 5815–5824, 2008.
[76]
M. C. Ruiz, O. C. Aristimu？o, Y. Díaz et al., “Intracellular disassembly of infectious rotavirus particles by depletion of Ca2+ sequestered in the endoplasmic reticulum at the end of virus cycle,” Virus Research, vol. 130, no. 1-2, pp. 140–150, 2007.
[77]
A. Irurzun, J. Arroyo, A. Alvarez, and L. Carrasco, “Enhanced intracellular calcium concentration during poliovirus infection,” Journal of Virology, vol. 69, no. 8, pp. 5142–5146, 1995.
[78]
R. Aldabe, A. Irurzun, and L. Carrasco, “Poliovirus protein 2BC increases cytosolic free calcium concentrations,” Journal of Virology, vol. 71, no. 8, pp. 6214–6217, 1997.
[79]
C. Brisac, F. Téoulé, A. Autret et al., “Calcium flux between the endoplasmic reticulum and mitochondrion contributes to poliovirus-induced apoptosis,” Journal of Virology, vol. 84, no. 23, pp. 12226–12235, 2010.
[80]
J. L. Nieva, A. Agirre, S. Nir, and L. Carrasco, “Mechanisms of membrane permeabilization by picornavirus 2B viroporin,” The FEBS Letters, vol. 552, no. 1, pp. 68–73, 2003.
[81]
F. J. M. van Kuppeveld, A. S. de Jong, W. J. G. Melchers, and P. H. G. M. Willems, “Enterovirus protein 2B po(u)res out the calcium: a viral strategy to survive?” Trends in Microbiology, vol. 13, no. 2, pp. 41–44, 2005.
[82]
A. S. de Jong, H. J. Visch, F. de Mattia et al., “The coxsackievirus 2B protein increases efflux of ions from the endoplasmic reticulum and Golgi, thereby inhibiting protein trafficking through the Golgi,” The Journal of Biological Chemistry, vol. 281, no. 20, pp. 14144–14150, 2006.
[83]
A. S. de Jong, F. de Mattia, M. M. van Dommelen et al., “Functional analysis of picornavirus 2B proteins: effects on calcium homeostasis and intracellular protein trafficking,” Journal of Virology, vol. 82, no. 7, pp. 3782–3790, 2008.
[84]
F. J. M. van Kuppeveld, J. G. J. Hoenderop, R. L. L. Smeets et al., “Coxsackievirus protein 2B modifies endoplasmic reticulum membrane and plasma membrane permeability and facilitates virus release,” EMBO Journal, vol. 16, no. 12, pp. 3519–3532, 1997.
[85]
M. Campanella, A. S. de Jong, K. W. H. Lanke et al., “The coxsackievirus 2B protein suppresses apoptotic host cell responses by manipulating intracellular Ca2+ homeostasis,” The Journal of Biological Chemistry, vol. 279, no. 18, pp. 18440–18450, 2004.
[86]
P. Bozidis, C. D. Williamson, D. S. Wong, and A. M. Colberg-Poley, “Trafficking of UL37 proteins into mitochondrion-associated membranes during permissive human cytomegalovirus infection,” Journal of Virology, vol. 84, no. 15, pp. 7898–7903, 2010.
[87]
R. Sharon-Friling, J. Goodhouse, A. M. Colberg-Poley, and T. Shenk, “Human cytomegalovirus pUL37x1 induces the release of endoplasmic reticulum calcium stores,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 50, pp. 19117–19122, 2006.
[88]
P. Pinton, D. Ferrari, E. Rapizzi, F. Di Virgilio, T. Pozzan, and R. Rizzuto, “The Ca2+ concentration of the endoplasmic reticulum is a key determinant of ceramide-induced apoptosis: significance for the molecular mechanism of Bcl-2 action,” EMBO Journal, vol. 20, no. 11, pp. 2690–2701, 2001.
[89]
A. R. Moise, J. R. Grant, T. Z. Vitalis, and W. A. Jefferies, “Adenovirus E3-6.7K maintains calcium homeostasis and prevents apoptosis and arachidonic acid release,” Journal of Virology, vol. 76, no. 4, pp. 1578–1587, 2002.
[90]
P. H. Chan, K. Niizuma, and H. Endo, “Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival,” Journal of Neurochemistry, vol. 109, no. 1, pp. 133–138, 2009.
[91]
F. Muller, A. R. Crofts, and D. M. Kramer, “Multiple Q-cycle bypass reactions at the Qo site of the cytochrome bc1 complex,” Biochemistry, vol. 41, no. 25, pp. 7866–7874, 2002.
[92]
F. L. Muller, A. G. Roberts, M. K. Bowman, and D. M. Kramer, “Architecture of the Q-o site of the cytochrome bc1 complex probed by superoxide production,” Biochemistry, vol. 42, no. 21, pp. 6493–6499, 2003.
[93]
F. L. Muller, Y. Liu, and H. van Remmen, “Complex III releases superoxide to both sides of the inner mitochondrial membrane,” The Journal of Biological Chemistry, vol. 279, no. 47, pp. 49064–49073, 2004.
[94]
V. P. Skulachev, “Bioenergetic aspects of apoptosis, necrosis and mitoptosis,” Apoptosis, vol. 11, no. 4, pp. 473–485, 2006.
[95]
J. St-Pierre, J. A. Buckingham, S. J. Roebuck, and M. D. Brand, “Topology of superoxide production from different sites in the mitochondrial electron transport chain,” The Journal of Biological Chemistry, vol. 277, no. 47, pp. 44784–44790, 2002.
[96]
D. Han, F. Antunes, R. Canali, D. Rettori, and E. Cadenas, “Voltage-dependent anion channels control the release of the superoxide anion from mitochondria to cytosol,” The Journal of Biological Chemistry, vol. 278, no. 8, pp. 5557–5563, 2003.
[97]
S. Miwa, J. St-Pierre, L. Partridge, and M. D. Brand, “Superoxide and hydrogen peroxide production by Drosophila mitochondria,” Free Radical Biology and Medicine, vol. 35, no. 8, pp. 938–948, 2003.
[98]
H. Tsutsui, T. Ide, and S. Kinugawa, “Mitochondrial oxidative stress, DNA damage, and heart failure,” Antioxidants and Redox Signaling, vol. 8, no. 9-10, pp. 1737–1744, 2006.
[99]
D. F. Stowe and A. K. S. Camara, “Mitochondrial reactive oxygen species production in excitable cells: modulators of mitochondrial and cell function,” Antioxidants and Redox Signaling, vol. 11, no. 6, pp. 1373–1414, 2009.
[100]
H. Tsutsui, S. Kinugawa, and S. Matsushima, “Mitochondrial oxidative stress and dysfunction in myocardial remodelling,” Cardiovascular Research, vol. 81, no. 3, pp. 449–456, 2009.
[101]
J. M. Taylor, D. Quilty, L. Banadyga, and M. Barry, “The vaccinia virus protein F1L interacts with Bim and inhibits activation of the pro-apoptotic protein Bax,” The Journal of Biological Chemistry, vol. 281, no. 51, pp. 39728–39739, 2006.
[102]
M. Ott, J. D. Robertson, V. Gogvadze, B. Zhivotovsky, and S. Orrenius, “Cytochrome c release from mitochondria proceeds by a two-step process,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 3, pp. 1259–1263, 2002.
[103]
S. Raha, A. T. Myint, L. Johnstone, and B. H. Robinson, “Control of oxygen free radical formation from mitochondrial complex I: roles for protein kinase A and pyruvate dehydrogenase kinase,” Free Radical Biology and Medicine, vol. 32, no. 5, pp. 421–430, 2002.
[104]
K. A. McGuire, A. U. Barlan, T. M. Griffin, and C. M. Wiethoff, “Adenovirus type 5 rupture of lysosomes leads to cathepsin B-dependent mitochondrial stress and production of reactive oxygen species,” Journal of Virology, vol. 85, no. 20, pp. 10806–10813, 2011.
[105]
S. Nishina, K. Hino, M. Korenaga et al., “Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription,” Gastroenterology, vol. 134, no. 1, pp. 226–238, 2008.
[106]
N. S. R. de Mochel, S. Seronello, S. H. Wang et al., “Hepatocyte NAD(P)H oxidases as an endogenous source of reactive oxygen species during hepatitis C virus infection,” Hepatology, vol. 52, no. 1, pp. 47–59, 2010.
[107]
M. J. Hsieh, Y. S. Hsieh, T. Y. Chen, and H. L. Chiou, “Hepatitis C virus E2 protein induce reactive oxygen species (ROS)-related fibrogenesis in the HSC-T6 hepatic stellate cell line,” Journal of Cellular Biochemistry, vol. 112, no. 1, pp. 233–243, 2010.
[108]
K. Machida, G. Mcnamara, K. T. Cheng et al., “Hepatitis C virus inhibits DNA damage repair through reactive oxygen and nitrogen species and by interfering with the ATM-NBS1/Mre11/Rad50 DNA repair pathway in monocytes and hepatocytes,” Journal of Immunology, vol. 185, no. 11, pp. 6985–6998, 2010.
[109]
I. I. Kruman, A. Nath, and M. P. Mattson, “HIV-1 protein tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress,” Experimental Neurology, vol. 154, no. 2, pp. 276–288, 1998.
[110]
M. A. Baugh, “HIV: reactive oxygen species, enveloped viruses and hyperbaric oxygen,” Medical Hypotheses, vol. 55, no. 3, pp. 232–238, 2000.
[111]
L. Gil, A. Tarinas, D. Hernandez et al., “Altered oxidative stress indexes related to disease progression marker in human immunodeficiency virus infected patients with antiretroviral therapy,” Biomedicine and Aging Pathology, vol. 1, no. 1, pp. 8–15, 2011.
[112]
C. W. Pyo, Y. L. Yang, N. K. Yoo, and S. Y. Choi, “Reactive oxygen species activate HIV long terminal repeat via post-translational control of NF-κB,” Biochemical and Biophysical Research Communications, vol. 376, no. 1, pp. 180–185, 2008.
[113]
W. Lin, G. Wu, S. Li et al., “HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NF κB,” The Journal of Biological Chemistry, vol. 286, no. 4, pp. 2665–2674, 2011.
[114]
S. Lassoued, B. Gargouri, A. E. F. El Feki, H. Attia, and J. van Pelt, “Transcription of the epstein-barr virus lytic cycle activator BZLF-1 during oxidative stress induction,” Biological Trace Element Research, vol. 137, no. 1, pp. 13–22, 2010.
[115]
S. Lassoued, R. B. Ameur, W. Ayadi, B. Gargouri, R. B. Mansour, and H. Attia, “Epstein-Barr virus induces an oxidative stress during the early stages of infection in B lymphocytes, epithelial, and lymphoblastoid cell lines,” Molecular and Cellular Biochemistry, vol. 313, no. 1-2, pp. 179–186, 2008.
[116]
B. Gargouri, J. van Pelt, A. E. F. El Feki, H. Attia, and S. Lassoued, “Induction of Epstein-Barr virus (EBV) lytic cycle in vitro causes oxidative stress in lymphoblastoid B cell lines,” Molecular and Cellular Biochemistry, vol. 324, no. 1-2, pp. 55–63, 2009.
[117]
Y. J. Kim, J. K. Jung, S. Y. Lee, and K. L. Jang, “Hepatitis B virus X protein overcomes stress-induced premature senescence by repressing p16INK4a expression via DNA methylation,” Cancer Letters, vol. 288, no. 2, pp. 226–235, 2010.
[118]
L. Hu, L. Chen, G. Yang et al., “HBx sensitizes cells to oxidative stress-induced apoptosis by accelerating the loss of Mcl-1 protein via caspase-3 cascade,” Molecular Cancer, vol. 10, article 43, 2011.
[119]
S. Schaedler, J. Krause, K. Himmelsbach et al., “Hepatitis B virus induces expression of antioxidant response element-regulated genes by activation of Nrf2,” The Journal of Biological Chemistry, vol. 285, no. 52, pp. 41074–41086, 2010.
[120]
R. Srisuttee, S. S. Koh, E. H. Park et al., “Up-regulation of Foxo4 mediated by hepatitis B virus X protein confers resistance to oxidative stress-induced cell death,” International Journal of Molecular Medicine, vol. 28, no. 2, pp. 255–260, 2011.
[121]
A. Bhargava, S. Khan, H. Panwar et al., “Occult hepatitis B virus infection with low viremia induces DNA damage, apoptosis and oxidative stress in peripheral blood lymphocytes,” Virus Research, vol. 153, no. 1, pp. 143–150, 2010.
[122]
Y. Ano, A. Sakudo, T. Kimata, R. Uraki, K. Sugiura, and T. Onodera, “Oxidative damage to neurons caused by the induction of microglial NADPH oxidase in encephalomyocarditis virus infection,” Neuroscience Letters, vol. 469, no. 1, pp. 39–43, 2010.
[123]
M. Colombini, E. Blachly-Dyson, and M. Forte, “VDAC, a channel in the outer mitochondrial membrane,” Ion channels, vol. 4, pp. 169–202, 1996.
[124]
M. Forte, E. Blachly-Dyson, and M. Colombini, “Structure and function of the yeast outer mitochondrial membrane channel, VDAC,” Society of General Physiologists Series, vol. 51, pp. 145–154, 1996.
[125]
S. Villinger, R. Briones, K. Giller et al., “Functional dynamics in the voltage-dependent anion channel,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 52, pp. 22546–22551, 2010.
[126]
E. Pebay-Peyroula, C. Dahout-Gonzalez, R. Kahn, V. Trézéguet, G. J. Lauquin, and G. Brandolin, “Structure of mitochondrial ADP/ATP carrier in complex with carboxyatractyloside,” Nature, vol. 426, no. 6962, pp. 39–44, 2003.
[127]
D. R. Hunter and R. A. Haworth, “The Ca2+-induced membrane transition in mitochondria. The protective mechanisms,” Archives of Biochemistry and Biophysics, vol. 195, no. 2, pp. 453–459, 1979.
[128]
K. D. Garlid, X. Sun, P. Paucek, and G. Woldegiorgis, “Mitochondrial cation transport systems,” Methods in Enzymology, vol. 260, pp. 331–348, 1995.
[129]
P. Bernardi, “Mitochondrial transport of cations: channels, exchangers, and permeability transition,” Physiological Reviews, vol. 79, no. 4, pp. 1127–1155, 1999.
[130]
A. P. Halestrap, “Calcium, mitochondria and reperfusion injury: a pore way to die,” Biochemical Society Transactions, vol. 34, no. 2, pp. 232–237, 2006.
[131]
K. Szydlowska and M. Tymianski, “Calcium, ischemia and excitotoxicity,” Cell Calcium, vol. 47, no. 2, pp. 122–129, 2010.
[132]
C. Piccoli, R. Scrima, G. Quarato et al., “Hepatitis C virus protein expression causes calcium-mediated mitochondrial bioenergetic dysfunction and nitro-oxidative stress,” Hepatology, vol. 46, no. 1, pp. 58–65, 2007.
[133]
M. Gac, J. Bigda, and T. W. Vahlenkamp, “Increased mitochondrial superoxide dismutase expression and lowered production of reactive oxygen species during rotavirus infection,” Virology, vol. 404, no. 2, pp. 293–303, 2010.
[134]
S. Carrère-Kremer, C. Montpellier-Pala, L. Cocquerel, C. Wychowski, F. Penin, and J. Dubuisson, “Subcellular localization and topology of the p7 polypeptide of hepatitis C virus,” Journal of Virology, vol. 76, no. 8, pp. 3720–3730, 2002.
[135]
M. E. Gonzalez and L. Carrasco, “Viroporins,” The FEBS Letters, vol. 552, no. 1, pp. 28–34, 2003.
[136]
D. Pavlovic, D. C. A. Neville, O. Argaud et al., “The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 10, pp. 6104–6108, 2003.
[137]
A. Azuma, A. Matsuo, T. Suzuki, T. Kurosawa, X. Zhang, and Y. Aida, “Human immunodeficiency virus type 1 Vpr induces cell cycle arrest at the G1 phase and apoptosis via disruption of mitochondrial function in rodent cells,” Microbes and Infection, vol. 8, no. 3, pp. 670–679, 2006.
[138]
E. Jacotot, L. Ravagnan, M. Loeffler et al., “The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore,” Journal of Experimental Medicine, vol. 191, no. 1, pp. 33–46, 2000.
[139]
A. Deniaud, C. Brenner, and G. Kroemer, “Mitochondrial membrane permeabilization by HIV-1 Vpr,” Mitochondrion, vol. 4, no. 2-3, pp. 223–233, 2004.
[140]
A. Macho, M. A. Calzado, L. Jiménez-Reina, E. Ceballos, J. León, and E. Mu？oz, “Susceptibility of HIV-1-TAT transfected cells to undergo apoptosis. Biochemical mechanisms,” Oncogene, vol. 18, no. 52, pp. 7543–7551, 1999.
[141]
H. Everett, M. Barry, X. Sun et al., “The myxoma poxvirus protein, M11L, prevents apoptosis by direct interaction with the mitochondrial permeability transition pore,” Journal of Experimental Medicine, vol. 196, no. 9, pp. 1127–1139, 2002.
[142]
H. Everett, M. Barry, S. F. Lee et al., “M11L: a novel mitochondria-localized protein of myxoma virus that blocks apoptosis of infected leukocytes,” Journal of Experimental Medicine, vol. 191, no. 9, pp. 1487–1498, 2000.
[143]
J. L. Macen, K. A. Graham, S. F. Lee, M. Schreiber, L. K. Boshkov, and G. McFadden, “Expression of the myxoma virus tumor necrosis factor receptor homologue and M11L genes is required to prevent virus-induced apoptosis in infected rabbit T lymphocytes,” Virology, vol. 218, no. 1, pp. 232–237, 1996.
[144]
S. T. Wasilenko, T. L. Stewart, A. F. A. Meyers, and M. Barry, “Vaccinia virus encodes a previously uncharacterized mitochondrial-associated inhibitor of apoptosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 2, pp. 14345–14350, 2003.
[145]
S. T. Wasilenko, L. Banadyga, D. Bond, and M. Barry, “The vaccinia virus F1L protein interacts with the proapoptotic protein Bak and inhibits Bak activation,” Journal of Virology, vol. 79, no. 22, pp. 14031–14043, 2005.
[146]
S. T. Wasilenko, A. F. A. Meyers, K. V. Helm, and M. Barry, “Vaccinia virus infection disarms the mitochondrion-mediated pathway of the apoptotic cascade by modulating the permeability transition pore,” Journal of Virology, vol. 75, no. 23, pp. 11437–11448, 2001.
[147]
K. Bruns, N. Studtrucker, A. Sharma et al., “Structural characterization and oligomerization of PB1-F2, a proapoptotic influenza A virus protein,” The Journal of Biological Chemistry, vol. 282, no. 1, pp. 353–363, 2007.
[148]
W. Chen, P. A. Calvo, D. Malide et al., “A novel influenza A virus mitochondrial protein that induces cell death,” Nature Medicine, vol. 7, no. 12, pp. 1306–1312, 2001.
[149]
J. S. Gibbs, D. Malide, F. Hornung, J. R. Bennink, and J. W. Yewdell, “The influenza A virus PB1-F2 protein targets the inner mitochondrial membrane via a predicted basic amphipathic helix that disrupts mitochondrial function,” Journal of Virology, vol. 77, no. 13, pp. 7214–7224, 2003.
[150]
M. Henkel, D. Mitzner, P. Henklein et al., “Proapoptotic influenza A virus protein PB1-F2 forms a nonselective ion channel,” PLoS ONE, vol. 5, no. 6, Article ID e11112, 2010.
[151]
M. Danishuddin, S. N. Khan, and A. U. Khan, “Molecular interactions between mitochondrial membrane proteins and the C-terminal domain of PB1-F2: an in silico approach,” Journal of Molecular Modeling, vol. 16, no. 3, pp. 535–541, 2010.
[152]
M. Silic-Benussi, O. Marin, R. Biasiotto, D. M. D'Agostino, and V. Ciminale, “Effects of human T-cell leukemia virus type 1 (HTLV-1) p13 on mitochondrial K+ permeability: a new member of the viroporin family?” The FEBS Letters, vol. 584, no. 10, pp. 2070–2075, 2010.
[153]
V. Ciminale, L. Zotti, D. M. D'Agostino et al., “Mitochondrial targeting of the p13(II) protein coded by the x-II ORF of human T-cell leukemia/lymphotropic virus type I (HTLV-I),” Oncogene, vol. 18, no. 31, pp. 4505–4514, 1999.
[154]
R. Biasiotto, P. Aguiari, R. Rizzuto, P. Pinton, D. M. D'Agostino, and V. Ciminale, “The p13 protein of human T cell leukemia virus type 1 (HTLV-1) modulates mitochondrial membrane potential and calcium uptake,” Biochimica et Biophysica Acta, vol. 1797, no. 6-7, pp. 945–951, 2010.
[155]
M. Silic-Benussi, I. Cavallari, T. Zorzan et al., “Suppression of tumor growth and cell proliferation by p13II, a mitochondrial protein of human T cell leukemia virus type 1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 17, pp. 6629–6634, 2004.
[156]
W. A. Nudson, J. Rovnak, M. Buechner, and S. L. Quackenbush, “Walleye dermal sarcoma virus Orf C is targeted to the mitochondria,” Journal of General Virology, vol. 84, no. 2, pp. 375–381, 2003.
[157]
E. White, “Mechanisms of apoptosis regulation by viral oncogenes in infection and tumorigenesis,” Cell Death and Differentiation, vol. 13, no. 8, pp. 1371–1377, 2006.
[158]
L. Galluzzi, C. Brenner, E. Morselli, Z. Touat, and G. Kroemer, “Viral control of mitochondrial apoptosis,” PLoS Pathogens, vol. 4, no. 5, Article ID e1000018, 2008.
[159]
C. A. Benedict, P. S. Norris, and C. F. Ware, “To kill or be killed: viral evasion of apoptosis,” Nature Immunology, vol. 3, no. 11, pp. 1013–1018, 2002.
[160]
S. Hay and G. Kannourakis, “A time to kill: viral manipulation of the cell death program,” Journal of General Virology, vol. 83, no. 7, pp. 1547–1564, 2002.
[161]
J. F. Kerr, A. H. Wyllie, and A. R. Currie, “Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics,” The British Journal of Cancer, vol. 26, no. 4, pp. 239–257, 1972.
[162]
E. Gulbins, S. Dreschers, and J. Bock, “Role of mitochondria in apoptosis,” Experimental Physiology, vol. 88, no. 1, pp. 85–90, 2003.
[163]
V. Borutaite, “Mitochondria as decision-makers in cell death,” Environmental and Molecular Mutagenesis, vol. 51, no. 5, pp. 406–416, 2010.
[164]
C. M. Sanfilippo and J. A. Blaho, “The facts of death,” International Reviews of Immunology, vol. 22, no. 5-6, pp. 327–340, 2003.
[165]
X. Liu, C. N. Kim, J. Yang, R. Jemmerson, and X. Wang, “Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c,” Cell, vol. 86, no. 1, pp. 147–157, 1996.
[166]
C. Castanier and D. Arnoult, “Mitochondrial dynamics during apoptosis,” Medecine/Sciences, vol. 26, no. 10, pp. 830–835, 2010.
[167]
H. Zou, W. J. Henzel, X. Liu, A. Lutschg, and X. Wang, “Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3,” Cell, vol. 90, no. 3, pp. 405–413, 1997.
[168]
M. Karbowski, “Mitochondria on guard: role of mitochondrial fusion and fission in the regulation of apoptosis,” Advances in Experimental Medicine and Biology, vol. 687, pp. 131–142, 2010.
[169]
X. M. Sun, M. MacFarlane, J. Zhuang, B. B. Wolf, D. R. Green, and G. M. Cohen, “Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis,” The Journal of Biological Chemistry, vol. 274, no. 8, pp. 5053–5060, 1999.
[170]
A. Ashkenazi and V. M. Dixit, “Death receptors: signaling and modulation,” Science, vol. 281, no. 5381, pp. 1305–1308, 1998.
[171]
K. F. Ferri and G. Kroemer, “Organelle-specific initiation of cell death pathways,” Nature Cell Biology, vol. 3, no. 11, pp. E255–E263, 2001.
[172]
L. Ravagnan, T. Roumier, and G. Kroemer, “Mitochondria, the killer organelles and their weapons,” Journal of Cellular Physiology, vol. 192, no. 2, pp. 131–137, 2002.
[173]
S. Ohta, “A multi-functional organelle mitochondrion is involved in cell death, proliferation and disease,” Current Medicinal Chemistry, vol. 10, no. 23, pp. 2485–2494, 2003.
[174]
N. N. Danial, A. Gimenez-Cassina, and D. Tondera, “Homeostatic functions of BCL-2 proteins beyond apoptosis,” Advances in Experimental Medicine and Biology, vol. 687, pp. 1–32, 2010.
[175]
M. E. Soriano and L. Scorrano, “The interplay between BCL-2 family proteins and mitochondrial morphology in the regulation of apoptosis,” Advances in Experimental Medicine and Biology, vol. 687, pp. 97–114, 2010.
[176]
S. Krishna, I. C. C. Low, and S. Pervaiz, “Regulation of mitochondrial metabolism: yet another facet in the biology of the oncoprotein Bcl-2,” Biochemical Journal, vol. 435, no. 3, pp. 545–551, 2011.
[177]
F. Llambi and D. R. Green, “Apoptosis and oncogenesis: give and take in the BCL-2 family,” Current Opinion in Genetics and Development, vol. 21, no. 1, pp. 12–20, 2011.
[178]
L. Scorrano and S. J. Korsmeyer, “Mechanisms of cytochrome c release by proapoptotic BCL-2 family members,” Biochemical and Biophysical Research Communications, vol. 304, no. 3, pp. 437–444, 2003.
[179]
M. Crompton, “Bax, Bid and the permeabilization of the mitochondrial outer membrane in apoptosis,” Current Opinion in Cell Biology, vol. 12, no. 4, pp. 414–419, 2000.
[180]
N. J. Waterhouse, J. E. Ricci, and D. R. Green, “And all of a sudden it's over: mitochondrial outer-membrane permeabilization in apoptosis,” Biochimie, vol. 84, no. 2-3, pp. 113–121, 2002.
[181]
A. S. Belzacq, H. L. A. Vieira, F. Verrier et al., “Bcl-2 and Bax modulate adenine nucleotide translocase activity,” Cancer Research, vol. 63, no. 2, pp. 541–546, 2003.
[182]
N. Zamzami and G. Kroemer, “Apoptosis: mitochondrial membrane permeabilization—the (w)hole story?” Current Biology, vol. 13, no. 2, pp. R71–R73, 2003.
[183]
G. Paradies, G. Petrosillo, V. Paradies, and F. M. Ruggiero, “Role of cardiolipin peroxidation and Ca2+ in mitochondrial dysfunction and disease,” Cell Calcium, vol. 45, no. 6, pp. 643–650, 2009.
[184]
A. Cuconati and E. White, “Viral homologs of BCL-2: role of apoptosis in the regulation of virus infection,” Genes and Development, vol. 16, no. 19, pp. 2465–2478, 2002.
[185]
B. J. Thomson, “Viruses and apoptosis,” International Journal of Experimental Pathology, vol. 82, no. 2, pp. 65–76, 2001.
[186]
D. Perez and E. White, “TNF-α signals apoptosis through a bid-dependent conformational change in Bax that is inhibited by E1B 19K,” Molecular Cell, vol. 6, no. 1, pp. 53–63, 2000.
[187]
B. M. Pützer, T. Stiewe, K. Parssanedjad, S. Rega, and H. Esche, “E1A is sufficient by itself to induce apoptosis independent of p53 and other adenoviral gene products,” Cell Death and Differentiation, vol. 7, no. 2, pp. 177–188, 2000.
[188]
L. Banadyga, J. Gerig, T. Stewart, and M. Barry, “Fowlpox virus encodes a Bcl-2 homologue that protects cells from apoptotic death through interaction with the proapoptotic protein bak,” Journal of Virology, vol. 81, no. 20, pp. 11032–11045, 2007.
[189]
A. Brun, C. Rivas, M. Esteban, J. M. Escribano, and C. Alonso, “African swine fever virus gene A179L, a viral homologue of bcl-2, protects cells from programmed cell death,” Virology, vol. 225, no. 1, pp. 227–230, 1996.
[190]
Y. Revilla, A. Cebrián, E. Baixerás, C. Martínez, E. Vi？uela, and M. L. Salas, “Inhibition of apoptosis by the African swine fever virus Bcl-2 homologue: role of the BH1 domain,” Virology, vol. 228, no. 2, pp. 400–404, 1997.
[191]
T. Derfuss, H. Fickenscher, M. S. Kraft et al., “Antiapoptotic activity of the herpesvirus saimiri-encoded Bcl-2 homolog: stabilization of mitochondria and inhibition of caspase-3-like activity,” Journal of Virology, vol. 72, no. 7, pp. 5897–5904, 1998.
[192]
W. L. Marshall, C. Yim, E. Gustafson et al., “Epstein-Barr virus encodes a novel homolog of the bcl-2 oncogene that inhibits apoptosis and associates with Bax and Bak,” Journal of Virology, vol. 73, no. 6, pp. 5181–5185, 1999.
[193]
X. M. Yin, Z. N. Oltvai, and S. J. Korsmeyer, “BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax,” Nature, vol. 369, no. 6478, pp. 321–323, 1994.
[194]
Z. Rahmani, K. W. Huh, R. Lasher, and A. Siddiqui, “Hepatitis B virus X protein colocalizes to mitochondria with a human voltage-dependent anion channel, HVDAC3, and alters its transmembrane potential,” Journal of Virology, vol. 74, no. 6, pp. 2840–2846, 2000.
[195]
Y. W. Lu and W. N. Chen, “Human hepatitis B virus X protein induces apoptosis in HepG2 cells: role of BH3 domain,” Biochemical and Biophysical Research Communications, vol. 338, no. 3, pp. 1551–1556, 2005.
[196]
Y. Tanaka, F. Kanai, T. Kawakami et al., “Interaction of the hepatitis B virus X protein (HBx) with heat shock protein 60 enhances HBx-mediated apoptosis,” Biochemical and Biophysical Research Communications, vol. 318, no. 2, pp. 461–469, 2004.
[197]
J. Diao, A. A. Khine, F. Sarangi et al., “X protein of hepatitis B virus inhibits Fas-mediated apoptosis and is associated with up-regulation of the SAPK/JNK pathway,” The Journal of Biological Chemistry, vol. 276, no. 11, pp. 8328–8340, 2001.
[198]
A. S. Kekule, U. Lauer, L. Weiss, B. Luber, and P. H. Hofschneider, “Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway,” Nature, vol. 361, no. 6414, pp. 742–745, 1993.
[199]
F. Su and R. J. Schneider, “Hepatitis B virus HBx protein activates transcription factor NF-κB by acting on multiple cytoplasmic inhibitors of rel-related proteins,” Journal of Virology, vol. 70, no. 7, pp. 4558–4566, 1996.
[200]
J. Benn, F. Su, M. Doria, and R. J. Schneider, “Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases,” Journal of Virology, vol. 70, no. 8, pp. 4978–4985, 1996.
[201]
F. Henkler, A. R. Lopes, M. Jones, and R. Koshy, “Erk-independent partial activation of AP-1 sites by the hepatitis B virus HBx protein,” Journal of General Virology, vol. 79, no. 11, pp. 2737–2742, 1998.
[202]
W. L. Shih, M. L. Kuo, S. E. Chuang, A. L. Cheng, and S. L. Doong, “Hepatitis b virus x protein inhibits transforming growth factor-β-induced apoptosis through the activation of phosphatidylinositol 3-kinase pathway,” The Journal of Biological Chemistry, vol. 275, no. 33, pp. 25858–25864, 2000.
[203]
J. Komano, M. Sugiura, and K. Takada, “Epstein-barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata,” Journal of Virology, vol. 72, no. 11, pp. 9150–9156, 1998.
[204]
D. S. Bellows, M. Howell, C. Pearson, S. A. Hazlewood, and J. M. Hardwick, “Epstein-Barr virus BALF1 is a BCL-2-like antagonist of the herpesvirus antiapoptotic BCL-2 proteins,” Journal of Virology, vol. 76, no. 5, pp. 2469–2479, 2002.
[205]
A. M. Flanagan and A. Letai, “BH3 domains define selective inhibitory interactions with BHRF-1 and KSHV BCL-2,” Cell Death and Differentiation, vol. 15, no. 3, pp. 580–588, 2008.
[206]
M. Thomas and L. Banks, “Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types,” Journal of General Virology, vol. 80, no. 6, pp. 1513–1517, 1999.
[207]
S. Jackson, C. Harwood, M. Thomas, L. Banks, and A. Storey, “Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins,” Genes and Development, vol. 14, no. 23, pp. 3065–3073, 2000.
[208]
S. Leverrier, D. Bergamaschi, L. Ghali et al., “Role of HPV E6 proteins in preventing UVB-induced release of pro-apoptotic factors from the mitochondria,” Apoptosis, vol. 12, no. 3, pp. 549–560, 2007.
[209]
Z. M. Sun, Y. Xiao, L. L. Ren, X. B. Lei, and J. W. Wang, “Enterovirus 71 induces apoptosis in a Bax dependent manner,” Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, vol. 25, no. 1, pp. 49–52, 2011.
[210]
C. S. Ilkow, I. S. Goping, and T. C. Hobman, “The rubella virus capsid is an anti-apoptotic protein that attenuates the pore-forming ability of Bax,” PLoS Pathogens, vol. 7, no. 2, Article ID e1001291, 2011.
[211]
V. S. Goldmacher, L. M. Bartle, A. Skaletskaya et al., “A cytomegalovirus-encoded mitochondria-localized inhibitor of apoptosis structurally unrelated to Bcl-2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 22, pp. 12536–12541, 1999.
[212]
D. Arnoult, L. M. Bartle, A. Skaletskaya et al., “Cytomegalovirus cell death suppressor vMIA blocks Bax- but not Bak-mediated apoptosis by binding and sequestering Bax at mitochondria,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 21, pp. 7988–7993, 2004.
[213]
D. Poncet, N. Larochette, A. Pauleau et al., “An anti-apoptotic viral protein that recruits Bax to mitochondria,” The Journal of Biological Chemistry, vol. 279, no. 21, pp. 22605–22614, 2004.
[214]
H. L. A. Vieira, A. S. Belzacq, D. Haouzi et al., “The adenine nucleotide translocator: a target of nitric oxide, peroxynitrite, and 4-hydroxynonenal,” Oncogene, vol. 20, no. 32, pp. 4305–4316, 2001.
[215]
P. Boya, M. C. Morales, R. Gonzalez-Polo et al., “The chemopreventive agent N-(4-hydroxyphenyl)retinamide induces apoptosis through a mitochondrial pathway regulated by proteins from the Bcl-2 family,” Oncogene, vol. 22, no. 40, pp. 6220–6230, 2003.
[216]
A. L. McCormick, V. L. Smith, D. Chow, and E. S. Mocarski, “Disruption of mitochondrial networks by the human cytomegalovirus UL37 gene product viral mitochondrion-localized inhibitor of apoptosis,” Journal of Virology, vol. 77, no. 1, pp. 631–641, 2003.
[217]
M. G. Katze, Y. He, and M. Gale Jr., “Viruses and interferon: a fight for supremacy,” Nature Reviews Immunology, vol. 2, no. 9, pp. 675–687, 2002.
[218]
M. Yoneyama, M. Kikuchi, T. Natsukawa et al., “The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses,” Nature Immunology, vol. 5, no. 7, pp. 730–737, 2004.
[219]
J. Andrejeva, K. S. Childs, D. F. Young et al., “The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-β promoter,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 49, pp. 17264–17269, 2004.
[220]
T. Maniatis, J. V. Falvo, T. H. Kim et al., “Structure and function of the interferon-β enhanceosome,” Cold Spring Harbor Symposia on Quantitative Biology, vol. 63, pp. 609–620, 1998.
[221]
I. Scott, “The role of mitochondria in the mammalian antiviral defense system,” Mitochondrion, vol. 10, no. 4, pp. 316–320, 2010.
[222]
C. Castanier and D. Arnoult, “Mitochondrial localization of viral proteins as a means to subvert host defense,” Biochimica et Biophysica Acta, vol. 1813, no. 4, pp. 575–583, 2011.
[223]
C. Wang, X. Liu, and B. Wei, “Mitochondrion: an emerging platform critical for host antiviral signaling,” Expert Opinion on Therapeutic Targets, vol. 15, no. 5, pp. 647–665, 2011.
[224]
R. B. Seth, L. Sun, and Z. J. Chen, “Antiviral innate immunity pathways,” Cell Research, vol. 16, no. 2, pp. 141–147, 2006.
[225]
L. G. Xu, Y. Y. Wang, K. J. Han, L. Y. Li, Z. Zhai, and H. B. Shu, “VISA is an adapter protein required for virus-triggered IFN-β signaling,” Molecular Cell, vol. 19, no. 6, pp. 727–740, 2005.
[226]
T. Kawai, K. Takahashi, S. Sato et al., “IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction,” Nature Immunology, vol. 6, no. 10, pp. 981–988, 2005.
[227]
E. Meylan, J. Curran, K. Hofmann et al., “Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus,” Nature, vol. 437, no. 7062, pp. 1167–1172, 2005.
[228]
Y. Xu, H. Zhong, and W. Shi, “MAVS protects cells from apoptosis by negatively regulating VDAC1,” Molecular and Cellular Biochemistry, vol. 375, no. 1-2, p. 219, 2010.
[229]
X. D. Li, L. Sun, R. B. Seth, G. Pineda, and Z. J. Chen, “Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 49, pp. 17717–17722, 2005.
[230]
E. Foy, K. Li, C. Wang et al., “Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease,” Science, vol. 300, no. 5622, pp. 1145–1148, 2003.
[231]
A. Breiman, N. Grandvaux, R. Lin et al., “Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKε,” Journal of Virology, vol. 79, no. 7, pp. 3969–3978, 2005.
[232]
E. Foy, K. Li, R. Sumpter Jr. et al., “Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 8, pp. 2986–2991, 2005.
[233]
B. Beames, D. Chavez, and R. E. Lanford, “GB virus B as a model for hepatitis C virus,” ILAR Journal, vol. 42, no. 2, pp. 152–160, 2001.
[234]
Z. Chen, Y. Benureau, R. Rijnbrand et al., “GB virus B disrupts RIG-I signaling by NS3/4A-mediated cleavage of the adaptor protein MAVS,” Journal of Virology, vol. 81, no. 2, pp. 964–976, 2007.
[235]
T. ？hman, J. Rintahaka, N. Kalkkinen, S. Matikainen, and T. A. Nyman, “Actin and RIG-I/MAVS signaling components translocate to mitochondria upon influenza a virus infection of human primary macrophages,” Journal of Immunology, vol. 182, no. 9, pp. 5682–5692, 2009.
[236]
D. A. Matthews and W. C. Russell, “Adenovirus core protein V interacts with p32—a protein which is associated with both the mitochondria and the nucleus,” Journal of General Virology, vol. 79, no. 7, pp. 1677–1685, 1998.
[237]
S. Cen, A. Khorchid, H. Javanbakht et al., “Incorporation of lysyl-tRNA synthetase into human immunodeficiency virus type 1,” Journal of Virology, vol. 75, no. 11, pp. 5043–5048, 2001.
[238]
E. Tolkunova, H. Park, J. Xia, M. P. King, and E. Davidson, “The human lysyl-tRNA synthetase gene encodes both the cytoplasmic and mitochondrial enzymes by means of an unusual: alternative splicing of the primary transcript,” The Journal of Biological Chemistry, vol. 275, no. 45, pp. 35063–35069, 2000.
[239]
M. Kaminska, V. Shalak, M. Francin, and M. Mirande, “Viral hijacking of mitochondrial lysyl-tRNA synthetase,” Journal of Virology, vol. 81, no. 1, pp. 68–73, 2007.
[240]
L. A. Stark and R. T. Hay, “Human immunodeficiency virus type 1 (HIV-1) viral protein R (Vpr) interacts with Lys-tRNA synthetase: implications for priming of HIV-1 reverse transcription,” Journal of Virology, vol. 72, no. 4, pp. 3037–3044, 1998.
[241]
L. Q. Qiu, P. Cresswell, and K. C. Chin, “Viperin is required for optimal Th2 responses and T-cell receptor-mediated activation of NF-κB and AP-1,” Blood, vol. 113, no. 15, pp. 3520–3529, 2009.
[242]
X. Wang, E. R. Hinson, and P. Cresswell, “The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts,” Cell Host and Microbe, vol. 2, no. 2, pp. 96–105, 2007.
[243]
J. Y. Seo, R. Yaneva, E. R. Hinson, and P. Cresswell, “Human cytomegalovirus directly induces the antiviral protein viperin to enhance infectivity,” Science, vol. 332, no. 6033, pp. 1093–1097, 2011.
[244]
S. Kim, H. Y. Kim, S. Lee et al., “Hepatitis B virus X protein induces perinuclear mitochondrial clustering in microtubule- and dynein-dependent manners,” Journal of Virology, vol. 81, no. 4, pp. 1714–1726, 2007.
[245]
Y. Nomura-Takigawa, M. Nagano-Fujii, L. Deng et al., “Non-structural protein 4A of Hepatitis C virus accumulates on mitochondria and renders the cells prone to undergoing mitochondria-mediated apoptosis,” Journal of General Virology, vol. 87, no. 7, pp. 1935–1945, 2006.
[246]
J. S. Radovanovi？, V. Todorovi？, I. Bori？i？, M. Jankovi？-Hladni, and A. Kora？, “Comparative ultrastructural studies on mitochondrial pathology in the liver of AIDS patients: clusters of mitochondria, protuberances, “minimitochondria,” vacuoles, and virus-like particles,” Ultrastructural Pathology, vol. 23, no. 1, pp. 19–24, 1999.
[247]
G. Rojo, M. Chamorro, M. L. Salas, E. Vinuela, J. M. Cuezva, and J. Salas, “Migration of mitochondria to viral assembly sites in African swine fever virus-infected cells,” Journal of Virology, vol. 72, no. 9, pp. 7583–7588, 1998.
[248]
D. C. Kelly, “Frog virus 3 replication: electron microscope observations on the sequence of infection in chick embryo fibroblasts,” Journal of General Virology, vol. 26, no. 1, pp. 71–86, 1975.
[249]
R. S. Fujinami and M. B. A. Oldstone, “Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity,” Science, vol. 230, no. 4729, pp. 1043–1045, 1985.
[250]
A. P. Kohm, K. G. Fuller, and S. D. Miller, “Mimicking the way to autoimmunity: an evolving theory of sequence and structural homology,” Trends in Microbiology, vol. 11, no. 3, pp. 101–105, 2003.
[251]
M. Monné, A. J. Robinson, C. Boes, M. E. Harbour, I. M. Fearnley, and E. R. S. Kunji, “The mimivirus genome encodes a mitochondrial carrier that transports dATP and dTTP,” Journal of Virology, vol. 81, no. 7, pp. 3181–3186, 2007.
[252]
H. A. Saffran, J. M. Pare, J. A. Corcoran, S. K. Weller, and J. R. Smiley, “Herpes simplex virus eliminates host mitochondrial DNA,” EMBO Reports, vol. 8, no. 2, pp. 188–193, 2007.
[253]
J. A. Corcoran, H. A. Saffran, B. A. Duguay, and J. R. Smiley, “Herpes simplex virus UL12.5 targets mitochondria through a mitochondrial localization sequence proximal to the N terminus,” Journal of Virology, vol. 83, no. 6, pp. 2601–2610, 2009.
[254]
A. Wiedmer, P. Wang, J. Zhou et al., “Epstein-Barr virus immediate-early protein Zta co-opts mitochondrial single-stranded DNA binding protein to promote viral and inhibit mitochondrial DNA replication,” Journal of Virology, vol. 82, no. 9, pp. 4647–4655, 2008.
[255]
K. Machida, K. T. Cheng, C. K. Lai, K. S. Jeng, V. M. Sung, and M. M. C. Lai, “Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STATS activation,” Journal of Virology, vol. 80, no. 14, pp. 7199–7207, 2006.
[256]
C. de Mendoza, L. Martin-Carbonero, P. Barreiro et al., “Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy,” AIDS, vol. 21, no. 5, pp. 583–588, 2007.
